Driving better and safer HER2-specific CARs for cancer therapy-Reference-Cited by-同舟云学术

Driving better and safer HER2-specific CARs for cancer therapy

Published:2017-04-29 Issue:37 Volume:8 Page:62730-62741
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Liu Xianqiang¹,Zhang Nan²,Shi Huan³

Affiliation:

1. Department of Breast and Thyroid Surgery, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China

2. Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China

3. Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong, P.R. China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Unprecedented Success of Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Hematological Malignancies;Cureus;2024-05-09

2. Prospects and challenges of CAR-T in the treatment of ovarian cancer;International Immunopharmacology;2024-05

3. Recent Advances and Challenges in Cancer Treatment with Car T Cell Therapy: A Novel Anti-cancer Strategy;BioNanoScience;2024-04-09

4. Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity;Journal for ImmunoTherapy of Cancer;2024-02

5. Anti-Cancer Potential of Transiently Transfected HER2-Specific Human Mixed CAR-T and NK Cell Populations in Experimental Models: Initial Studies on Fucosylated Chondroitin Sulfate Usage for Safer Treatment;Biomedicines;2023-09-18